Immune Checkpoint Inhibitor-Associated Pericarditis
Immune Checkpoint Inhibitor-Associated Pericarditis
复制标题
DOI：
10.1016/j.jtho.2019.02.026
复制
发表时间：
2019-06-01
影响因子：
20.4
通讯作者：
Rimm, David L.
中科院分区：
文献类型：
--
作者：
Altan, Mehmet;Toki, Maria I.;Rimm, David L.
免疫检查点抑制剂的副作用（称为免疫相关不良事件）相对常见，但免疫检查点抑制剂介导的心脏毒性很少见;然而，它们可能是严重的，可能是致命的。心包炎是免疫治疗的一种罕见心脏毒性，其诱发因素仍不清楚。在这里，我们报告了3例NSCLC患者在程序性死亡1/程序性死亡配体1+/- CTLA-4抑制剂治疗期间发生心包炎。我们回顾了这三例病例的临床表现和前两例患者尸检的组织病理学结果，以及第三例从心包炎事件中恢复的患者的心包开窗手术中获得的心包取样。我们还讨论了潜在的机制，以及什么是已知的心包炎继发于免疫相关的不良事件。(C)2019年国际肺癌研究协会。由爱思唯尔公司出版All rights reserved.
Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor-mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.